Cefditoren

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cefditoren
Cefditoren.svg
Clinical data
Trade names Spectracef
AHFS/Drugs.com Monograph
MedlinePlus a605003
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard 100.214.754
Chemical and physical data
Formula C19H18N6O5S3
Molar mass 506.58 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Cefditoren is a third-generation cephalosporin antibiotic for oral use. It is commonly marketed under the trade name Spectracef by Vansen Pharma Inc.

Cefditoren is also marketed under the name Meiact by Meiji Seika Pharma Co., Ltd.[1]

Spectrum of bacterial susceptibility[edit]

Cefditoren has a broad spectrum of activity and has been used to treat bacterial infections of the skin and respiratory tract, including bronchitis, pneumonia, and tonsillitis. The following represents MIC susceptibility data for a few medically significant microorganisms.

  • Haemophilus influenzae: ≥0.063 - 0.25 μg/ml
  • Staphylcoccus aureus: 0.25 - >128 μg/ml (includes MRSA)
  • Streptococcus pyogenes: ≤0.004 - 2 μg/ml[2]

Cefditoren is a broad-spectrum antibiotic against Gram-negative and Gram-positive bacteria, but does not have antibacterial activity against Pseudomonas aeruginosa.[3]

Clinical use[edit]

Main article: Cephalosporin

Indications[edit]

Cefditoren is used to treat uncomplicated skin and skin structure infections, community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, pharyngitis, and tonsillitis.

Formulations[edit]

Cefditoren is available as 200- and 400-mg tablets. It can be formulated as the prodrug cefditoren pivoxil.

Chemical structure of cefditoren pivoxil

References[edit]

External links[edit]